Acorda Therapeutics, a biopharmaceutical company dedicated to combating neurological disorders, has made significant strides over its 26-year history. One of its most notable achievements is the development and commercialization of Ampyra (dalfampridine), an oral drug that enhances the walking capabilities of adults with MS. Acorda has also launched Inbrija, an inhaled levodopa targeted at treating OFF periods in Parkinson's disease patients utilizing a carbidopa/levodopa regimen, in the US market. While the company markets Ampyra as Fampyra in areas including Europe, Asia, and the Americas, its ambitions extend far beyond this. Notably, Acorda's pipeline contains Cimaglermin alfa (GGF2), a member of the neuregulin growth factor family currently undergoing Phase 1 clinical trials aimed at aiding neurological injury recovery and improving heart function in animal models of heart failure. Acorda has also inked a collaboration and license agreement alongside Biogen, Inc. to co-develop and commercialize Ampyra. These relationships are key in Acorda's quest to address critical neurological disorders. Headquartered in New York's Pearl River district, Acorda received its incorporation in 1995. With its impressive pipeline and successful track record, it's clear that the company will continue to be at the forefront of the fight against neurological disorders.
Acorda Therapeutics's ticker is ACOR
The company's shares trade on the NASDAQ stock exchange
They are based in Ardsley, New York
There are 201-500 employees working at Acorda Therapeutics
It is acorda.com
Acorda Therapeutics is in the Healthcare sector
Acorda Therapeutics is in the Biotechnology industry
The following five companies are Acorda Therapeutics's industry peers: